Bavarian Nordic To Raise $250m For Phase III RSV Vaccine Study
Self-Funded Trial To Begin Next Year
Executive Summary
The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022
You may also be interested in...
J&J Sets The Pace In Race To $10bn RSV Vaccine Market
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.
Bavarian Nordic Seeks Partner After RSV Jab Generates Glowing Phase II Data
Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.
Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program
Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.